Insmed raises outlook as BRINSUPRI launch accelerates

Transcript intelligence

What changed

Management raised full-year revenue guidance to $1.25 billion-$1.4 billion and increased the BRINSUPRI peak-sales projection to more than $7 billion. The quarter also added TPIP open-label extension results and FDA clearance for the INS1033 IND, while ARIKAYCE's supplemental NDA remains part of the expansion plan.

Guidance delta

Raised. Full-year revenue guidance increased to $1.25 billion-$1.4 billion, and the BRINSUPRI peak-sales projection increased to more than $7 billion.

Key takeaways

• BRINSUPRI new-patient starts are approximately 7,000 per quarter and the launch is exceeding expectations.
• ARIKAYCE continues stable growth, with a supplemental NDA for earlier-line MAC disease and a planned Japan submission.
• TPIP data across PAH and other indications support continued Phase III development and a potential multi-indication opportunity.
• Management cited a $1.2 billion cash balance and expects cash-flow positivity in 2027 without new financing.
• Diagnostic initiatives, direct-to-consumer advertising and commercial expansion are intended to support demand.

Management priorities

• Continue the BRINSUPRI launch, including diagnostic initiatives and direct-to-consumer advertising.
• Advance TPIP Phase III programs in PAH, PH-ILD, PPF and IPF, including dose-flexibility studies.
• Submit and pursue regulatory expansion for ARIKAYCE and planned submissions in Japan.
• Begin INS1033 clinical development in rheumatoid arthritis, ulcerative colitis and COPD.
• Evaluate external M&A opportunities meeting first- or best-in-class criteria.